|
Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® & Varilrix®. |
Combined Measles, Mumps, Rubella, Varicella Vaccine |
208136/039 |
NCT00406211 |
Measles; Mumps; Rubella; Varicella |
Phase 3 |
|
|
|
|
This is a Year 1 follow-up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided. |
February 2015 |